FrancophonIA/ELRC3.0 huggingface dataset:
English: Hypertensive crisis with encephalopathy-like symptoms (e.g. headaches and confused state, sensorimotor disorders - such as speech disturbance or impaired gait - up to tonoclonic seizures) may also occur in individual patients with otherwise normal or low blood pressure (see section 4.4).
Estonian: Ka muidu normaalse või madala vererõhuga patsientidel võib tekkida hüpertensiivne kriis entsefalopaatiale iseloomulike sümptomitega (peavalud, segasusseisund, sensomotoorsed häired: kõne- ja kõndimishäired kuni toonilis-klooniliste krampideni) (vt lõik 4.4).
English: The weekly dose can also be divided into daily doses.
Estonian: Nädalaannuse võib jaotada ka ööpäevasteks annusteks.
English: One ml solution for injection contains 6667 IU epoetin beta.
Estonian: Üks ml süstelahust sisaldab 6667 RÜ epoetiin beetat.
English: NeoRecormon contains phenylalanine, benzyl alcohol and sodium This medicine contains phenylalanine.
Estonian: NeoRecormon sisaldab fenüülalaniini, bensüülalkoholi ja naatriumit.
English: If signs and symptoms suggestive of these reactions appear, NeoRecormon should be withdrawn immediately and an alternative treatement considered.If the patient has developed a severe cutaneous skin reaction such as SJS orTEN due to the use of NeoRecormon, treatment with ESA must not be restarted in this patient at any time.
Estonian: Kui patsiendil on kasutamise tõttu tekkinud raske nahareaktsioon, nagu SJS või TEN, ei tohi ravi sellel patsiendil mitte kunagi uuesti alustada.
English: Adverse reactions attributed to the treatment with NeoRecormon in controlled clinical trials in patients in an autologous blood predonation programme System organ class
Estonian: NeoRecormon-ravist tingitud kõrvaltoimed kontrollitud kliinilistes uuringutes patsientidel, kellel viiakse läbi autoloogse vere kogumist Organsüsteemi klass
English: NeoRecormon 500 IU NeoRecormon 2000 IU NeoRecormon 3000 IU NeoRecormon 4000 IU NeoRecormon 5000 IU NeoRecormon 6000 IU NeoRecormon 10,000 IU NeoRecormon 20,000 IU NeoRecormon 30,000 IU solution for injection in pre-filled syringe Epoetin beta
Estonian: NeoRecormon 500 RÜ NeoRecormon 2000 RÜ NeoRecormon 3000 RÜ NeoRecormon 4000 RÜ NeoRecormon 5000 RÜ NeoRecormon 6000 RÜ NeoRecormon 10 000 RÜ NeoRecormon 20 000 RÜ NeoRecormon 30 000 RÜ Süstelahus süstlis Epoetiin beeta
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/
Estonian: Infoleht on viimati uuendatud Täpne teave selle ravimi kohta on Euroopa Ravimiameti kodulehel http://www.ema.europa.eu/
English: Sodium chloride, Polysorbate 20, Sodium dihydrogen phosphate, Disodium hydrogen phosphate, Calcium chloride, Glycine,
Estonian: Naatriumkloriid, Polüsorbaat 20, Naatriumdivesinikfosfaat, Dinaatriumvesinikfosfaat, Kaltsiumkloriid, Glütsiin,
English: NeoRecormon Multidose 50,000 IU lyophilisate and solvent for solution for injection Epoetin beta
Estonian: NeoRecormon Multidose 50 000 RÜ Süstelahuse lüofilisaat ja lahusti Epoetiin beeta
English: - Increasing the yield of autologous blood from patients in a pre-donation programme.
Estonian: - Autoloogse punavere hulga suurendamine mõõduka aneemiaga patsientidel enne operatsioonieelset autoloogse vere kogumist (predonatsiooni).
English: · Keep your syringe out of direct sunlight.
Estonian: • Hoidke NeoRecormoni süstlit otsese päikesevalguse eest kaitstult.
English: · Pure red cell aplasia (PRCA) caused by neutralising antibodies has been observed during erythropoietin therapy, including in isolated cases during therapy with NeoRecormon.
Estonian: Isoleeritud erütrotsütaarne aplaasia (pure red cell aplasia, PRCA) Seoses erütropoetiinraviga, sh ka NeoRecormoniga, on teatatud PRCA tekkest, mis on põhjustatud erütropoetiinivastastest neutraliseerivatest antikehadest.
English: · Do not hold the plunger while you remove the needle cap. · Do not touch the needle after removing the needle cap. · Do not re-cap the needle.
Estonian: • Ärge puudutage nõela pärast nõelakatte eemaldamist.
English: 4 Inspect the syringe and needle closely · Check the syringe and needle for any damage.
Estonian: 4 Kontrollige süstlit ja nõela hoolikalt.
English: What you need to know before you use NeoRecormon Do not use NeoRecormon · if you are allergic to epoetin beta or any of the other ingredients of this medicine (listed in section 6)
Estonian: • kui olete epoetiin beeta või selle ravimi mis tahes koostisosa (loetletud lõigus 6) suhtes allergiline
English: One ml solution for injection contains 1667 IU epoetin beta.
Estonian: Üks ml süstelahust sisaldab 1667 RÜ epoetiin beetat.
English: - Intravenous administration: The initial dosage is 3 x 40 IU/kg per week.
Estonian: - Intravenoosne manustamine: Algannus on 40 RÜ/kg 3 korda nädalas.
English: Early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid, for example, should be considered in chronic renal failure patients at risk of shunt thrombosis.
Estonian: Kroonilise neerupuudulikkusega patsientidele, kelle puhul on oht shundi tromboseerumiseks, soovitatakse shundi kontrollimiseks ja tromboosi profülaktikaks manustada näiteks atsetüülsalitsüülhapet.
English: The initial dosage is 3 x 40 IU/kg per week.
Estonian: Algannus on 40 RÜ/kg 3 korda nädalas.
English: L-Glutamic acid,
Estonian: L-glutamiinhape,
English: Do not take a double dose to make up for any forgotten doses.
Estonian: Ärge manustage kahekordset annust, kui ravim jäi eelmisel korral süstimata.
English: If the haemoglobin level continues to increase, therapy should be interrupted until the hemoglobin level begins to decrease, at which point therapy should be restarted at a dose approximately 25 % below the previously administered dose.
Estonian: Kui hemoglobiinisisalduse suurenemine jätkub, tuleb ravi katkestada, kuni hemoglobiinitase hakkab langema.
English: Potassium elevation has been reported in a few uraemic patients receiving NeoRecormon, though causality has not been established.
Estonian: Mõnel ureemilisel patsiendil on täheldatud hüperkaleemiat, mille põhjus on ebaselge.
English: If any of these apply to you, or might apply, tell your doctor at once.
Estonian: Kui midagi eeltoodust käib teie kohta, rääkige sellest kohe arstile.
English: · Do not touch the plunger while inserting the needle into the skin · Do not insert the needle through clothing.
Estonian: • Ärge sisestage nõela läbi riiete.
English: Medicinal product contains phenylalanine and sodium and solvent contains benzyl alcohol, see leaflet for further information.
Estonian: 1 ampull sisaldab lahustit (bensüülalkohol ja bensalkooniumkloriid süstevees) Ravim sisaldab fenüülalaniini ja naatriumit ning lahusti sisaldab bensüülalkoholi, lisainformatsioon vt pakendi infoleht
English: · If you get any side effects, talk to your doctor or pharmacist.
Estonian: • Kui teil tekib ükskõik milline kõrvaltoime, pidage nõu oma arsti või apteekriga.
English: The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve: The required amount of pre-donated blood depends on the anticipated blood loss, use of blood conserving procedures and the physical condition of the patient.
Estonian: Vajalik autoloogse vere hulk sõltub eeldatavatest verekaotusest, vere säilitamise protseduuride kasutamisest ja patsiendi seisundist.
English: This medicinal product contains less than 1 mmol sodium (23 mg) per syringe, i.e. essentially “sodium-free”.
Estonian: See ravimpreparaat sisaldab alla 1 mmol naatriumit (23 mg) süstli kohta, st on praktiliselt "naatriumivaba".
English: This may be given as one injection per week, or in divided doses as 3 to 7 injections per week.
Estonian: Selle võib manustada ühe süstena nädalas või väiksemateks annusteks jaotatuna 3...7 süstena nädalas.
English: In isolated cases, neutralising anti erythropoietin antibody-mediated pure red cell aplasia (PRCA) associated with NeoRecormon therapy has been reported.
Estonian: Üksikjuhtudel on teatatud NeoRecormon-raviga seotud erütropoetiinivastastest neutraliseerivatest antikehadest põhjustatud isoleeritud erütrotsütaarse aplaasia (IEA) tekkest.
English: One ml solution for injection contains 20,000 IU epoetin beta.
Estonian: Üks ml süstelahust sisaldab 20 000 RÜ epoetiin beetat.
English: Sodium dihydrogen phosphate dihydrate, Disodium phosphate dodecahyrate, Calcium chloride dihydrate, Glycine,
Estonian: Naatriumdivesinikfosfaatdihüdraat, Dinaatriumfosfaatdodekahüdraat, Kaltsiumkloriiddihüdraat, Glütsiin,
English: INFORMATION IN BRAILLE neorecormon 20.000 IU
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) neorecormon 20 000 RÜ
English: INFORMATION IN BRAILLE neorecormon 2000 IU
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) neorecormon 2000 RÜ
English: Pre-filled syringe (Type I glass) with a tip cap and a plunger stopper (teflonised rubber).
Estonian: I tüüpi klaasist süstel otsakorgi ja teflonkattega kummist kolvikorgiga.
English: · Do not inject into vein or into a muscle
Estonian: • Ärge süstige veeni ega lihasesse.
English: A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Estonian: II LISA A. BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJA(D) JA RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST VASTUTAV(AD) TOOTJA(D) B. HANKE- JA KASUTUSTINGIMUSED VÕI PIIRANGUD C. MÜÜGILOA MUUD TINGIMUSED JA NÕUDED D. RAVIMPREPARAADI OHUTU JA EFEKTIIVSE KASUTAMISE TINGIMUSED JA PIIRANGUD
English: MARKETING AUTHORISATION NUMBER EU/1/97/031/019
Estonian: MÜÜGILOA NUMBER EU/1/97/031/019
English: Not included in the box: · 1 alcohol swab.
Estonian: • 1 alkoholiga niisutatud lapp,
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 vial contains 50,000 IU epoetin beta.
Estonian: TOIMEAINE(TE) SISALDUS 1 viaal sisaldab 50 000 RÜ epoetiin beetat.
English: Treatment must be started under the supervision of your doctor.
Estonian: Ravi NeoRecormoniga tuleb alustada teie raviarsti järelevalve all.
English: Take hold of the stem and snap off away from you.
Estonian: Võtta ampullikaelast kinni ja murda see katki suunaga endast eemale.
English: Change vein with each injection to prevent soreness in one spot.
Estonian: Et vältida ühe koha valulikuks muutumist, tehke iga süst erinevasse veeni.
English: If you have high or rising potassium levels your doctor may reconsider your treatment · your blood platelet count.
Estonian: Kõrge või suureneva kaaliumi sisalduse korral võib arst uuesti otsustada ravi jätkamise üle.
English: - Subcutaneous administration: - The initial dosage is 3 x 20 IU/kg body weight per week.
Estonian: Korrektsioonifaas - Subkutaanne manustamine: - Algannus on 20 RÜ/kg 3 korda nädalas.
English: NeoRecormon 2000 IU solution for injection in pre-filled syringe NeoRecormon 3000 IU solution for injection in pre-filled syringe NeoRecormon 4000 IU solution for injection in pre-filled syringe NeoRecormon 5000 IU solution for injection in pre-filled syringe NeoRecormon 6000 IU solution for injection in pre-filled syringe NeoRecormon 10,000 IU solution for injection in pre-filled syringe NeoRecormon 20,000 IU solution for injection in pre-filled syringe NeoRecormon 30,000 IU solution for injection in pre-filled syringe
Estonian: NeoRecormon, 500 RÜ, süstelahus süstlis NeoRecormon 2000 RÜ, süstelahus süstlis NeoRecormon 3000 RÜ, süstelahus süstlis NeoRecormon 4000 RÜ, süstelahus süstlis NeoRecormon 5000 RÜ, süstelahus süstlis NeoRecormon 6000 RÜ, süstelahus süstlis NeoRecormon 10 000 RÜ, süstelahus süstlis NeoRecormon 20 000 RÜ, süstelahus süstlis NeoRecormon 30 000 RÜ, süstelahus süstlis
English: 1 prefilled syringe with one needle (30G1/2) or 6 pre-filled syringes with 6 needles (30G1/2).
Estonian: NeoRecormon 500 RÜ 1 süstel koos ühe nõelaga (30G1/2) või 6 süstlit koos 6 nõelaga (30G1/2).
English: One ml solution for injection contains 50,000 IU epoetin beta.
Estonian: Üks ml süstelahust sisaldab 50 000 RÜ epoetiin beetat.
English: One ml of reconstituted solution contains 5000 IU epoetin beta.
Estonian: Üks ml valmislahust sisaldab 5000 RÜ epoetiin beetat.
English: NeoRecormon is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does.
Estonian: Eriline ettevaatus on vajalik tarvitamisel koos teiste punaliblede tootmist stimuleerivate ravimitega: NeoRecormon kuulub ravimite rühma, mis stimuleerivad punaliblede tootmist nagu inimese erütropoetiin.
English: Excipients
Estonian: Meespatsiendid
English: Side effects which can affect any patient · Most people (very common, may affect more than 1 in 10 people) get lower levels of iron in their blood.
Estonian: • Enamikel patsientidel (väga sage, võib tekkida rohkem kui ühel inimesel 10st) väheneb vere rauasisaldus.
English: 1 pre-filled syringe (0.3 ml) and 1 needle (30G1/2)
Estonian: 1 süstel (0,3 ml) ja 1 süstlanõel (30G1/2)
English: INFORMATION IN BRAILLE neorecormon 500 IU
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) neorecormon 500 RÜ
English: 14 Adjust to your prescribed dose by slowly pushing the plunger.
Estonian: 14 Lükake kolbi aeglaselt ülespoole kuni määratud annuse tähiseni.
English: Keep the vials in the outer carton, in order to protect from light.
Estonian: Hoida viaal välispakendis, et kaitsta ravimit valguse eest.
English: The dosage may be increased every 4 weeks by 3 x 20 IU/kg and week if the increase of Hb is not adequate (< 0.25 g/dl per week).
Estonian: Juhul, kui Hb tõus ei ole küllaldane (alla 0,25 g/dl nädalas), võib annust suurendada 3x20 RÜ/kg võrra nädalas 4-nädalase intervalliga.
English: 6 pre-filled syringes (0.3 ml) and 6 needles (30G1/2)
Estonian: 6 süstlit (0,3 ml) ja 6 süstlanõela (30G1/2)
English: Patients who are stable on a once weekly dosing regimen may be switched to once every two weeks administration.
Estonian: Stabiilsetele patsientidele võib NeoRecormon´i hakata manustama üks kord iga kahe nädala järel.
English: INFORMATION IN BRAILLE neorecormon 50,000 IU
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) neorecormon 50 000 RÜ
English: Remove the cap from the syringe.
Estonian: Eemaldada süstlilt otsik.
English: · Do not handle the syringe by holding the plunger or needle cap.
Estonian: • Ärge hoidke süstlit kolvist ega nõelakattest.
English: The weekly dose can be given as one injection per week or in divided doses 3 to 7 times per week.
Estonian: Nädala annuse võib manustada ühe süstena nädalas või jaotatuna 3...7 korrale nädalas.
English: Anaemic patients with chronic renal failure
Estonian: Täiendavad kõrvaltoimed kroonilise neeruhaigusega (renaalse aneemiaga) patsientidel
English: If you think you have missed an injection, or been injected too little, talk to your doctor.
Estonian: Kui te unustate NeoRecormoni kasutada Kui arvate, et süst on vahele jäänud või teile on süstitud liiga vähe ravimit, pidage nõu oma arstiga.
English: One ml solution for injection contains 10,000 IU epoetin beta.
Estonian: Üks ml süstelahust sisaldab 10000 RÜ epoetiin beetat.
English: INFORMATION IN BRAILLE neorecormon 6000 IU
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) neorecormon 6000 RÜ
English: Other in-use storage times and conditions are the responsibility of the user.
Estonian: Kasutaja on vastutav eelpool toodud nõuete järgimise eest.
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 pre-filled syringe contains 2000 IU epoetin beta.
Estonian: TOIMEAINE(TE) SISALDUS 1 süstel sisaldab 2000 RÜ epoetiin beetat.
English: Platelet counts and haemoglobin level should also be monitored at regular intervals in cancer patients.
Estonian: Vähihaigetel tuleb regulaarsete ajavahemike järel jälgida trombotsüütide arvu ja hemoglobiinisisaldust.
English: Adverse reactions attributed to the treatment with NeoRecormon in controlled clinical trials in cancer patients System organ class
Estonian: NeoRecormon-ravist tingitud kõrvaltoimed kontrollitud kliinilistes uuringutes vähihaigetel
English: Adverse reactions attributed to the treatment with NeoRecormon in controlled clinical trials in CKD patients System organ class
Estonian: NeoRecormon-ravist tingitud kõrvaltoimed kontrollitud kliinilistes uuringutes kroonilise neeruhaigusega patsientidel
English: MINIMUM PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED VÄLISPAKEND
English: Serious skin reaction including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment.
Estonian: Epoetiinraviga seoses on teatatud tõsistest nahareaktsioonidest, sealhulgas Stevensi-Johnsoni sündroomist (SJS) ja toksilisest epidermaalsest nekrolüüsist (TEN).
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION NeoRecormon Multidose 50,000 IU lyophilisate for injection epoetin beta
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) NeoRecormon Multidose 50 000 RÜ süstevedeliku lüofilisaat epoetiin beeta i.v./s.c.
English: Clean the skin at the site of injection using an alcohol wipe.
Estonian: Puhastada nahk süstepiirkonnas alkoholiga immutatud tampooni abil.
English: Serum potassium and phosphate levels should be monitored regularly during NeoRecormon therapy.
Estonian: Ravi ajal tuleb regulaarselt jälgida seerumi kaaliumi ja fosfaatide sisaldust.
English: For subcutaneous injection, clean the skin at the site of injection using an alcohol wipe.
Estonian: Naha alla süstimiseks tuleb süstekoht eelnevalt puhastada alkoholiga immutatud tampooni abil.
English: (5) Attach the device to the vial until the snap lock clicks home. (6) Put the green needle on the syringe contained in the package and remove the needle cover.
Estonian: (6) Ühendada roheline nõel pakendis kaasasolevale süstlile ja eemaldada süstlikate.
English: · Adults with symptomatic anaemia receiving chemotherapy for cancer
Estonian: Sümptomaatilise kemoteraapiast tingitud aneemia ravi vähktõvega patsientidel
English: NeoRecormon 2000 IU solution for injection in pre-filled syringe One pre-filled syringe with 0.3 ml solution for injection contains 2000 international units (IU) corresponding to 16.6 micrograms epoetin beta* (recombinant human erythropoietin).
Estonian: Üks süstel 0,3 ml süstelahusega sisaldab 2000 RÜ (vastab 16,6 µg epoetiin beetale) epoetiin beetat* (rekombinantne inimese erütropoetiin).
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 pre-filled syringe contains 6000 IU epoetin beta.
Estonian: TOIMEAINE(TE) SISALDUS 1 süstel sisaldab 6000 RÜ epoetiin beetat.
English: NeoRecormon 6000 IU solution for injection in pre-filled syringe One pre-filled syringe with 0.3 ml solution for injection contains 6000 international units (IU) corresponding to 49.8 micrograms epoetin beta* (recombinant human erythropoietin).
Estonian: Üks süstel 0,3 ml süstelahusega sisaldab 6000 RÜ (vastab 49,8 µg epoetiin beetale) epoetiin beetat* (rekombinantne inimese erütropoetiin).
English: Inject the NeoRecormon solution.
Estonian: Süstida NeoRecormon´i lahus.
English: In clinical trials, an increased risk of death and serious cardiovascular events or cerebrovascular events including stroke was observed when erythropoiesis stimulating agents (ESAs) were administered to target a haemoglobin of greater than 12 g/dl (7.5 mmol/l).
Estonian: Kliinilistes uuringutes täheldati erütropoeesi stimuleerivate ainete (ESAde) manustamisel hemoglobiinisisalduse sihtväärtuseni üle 12 g/dl (7,5 mmol/l) suurenenud riski surma ja raskete kardiovaskulaarsete või tserebrovaskulaarsete tüsistuste, sealhulgas insuldi tekkeks.
English: · Keep the vials in the outer carton in order to protect from light.
Estonian: • Hoida viaale välispakendis, valguse eest kaitstult.
English: INFORMATION IN BRAILLE neorecormon 4000 IU
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) neorecormon 4000 RÜ
English: NeoRecormon 30,000 IU solution for injection in pre-filled syringe One pre-filled syringe with 0.6 ml solution for injection contains 30,000 international units (IU) corresponding to 250 micrograms epoetin beta* (recombinant human erythropoietin).
Estonian: Üks süstel 0,6 ml süstelahusega sisaldab 30 000 RÜ (vastab 250 µg epoetiin beetale) epoetiin beetat* (rekombinantne inimese erütropoetiin).
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 pre-filled syringe contains 5000 IU epoetin beta.
Estonian: TOIMEAINE(TE) SISALDUS 1 süstel sisaldab 5000 RÜ epoetiin beetat.
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 pre-filled syringe contains 20,000 IU epoetin beta.
Estonian: TOIMEAINE(TE) SISALDUS 1 süstel sisaldab 20 000 RÜ epoetiin beetat.
English: 1 pre-filled syringe (0.3 ml) and 1 needle (27G1/2)
Estonian: 1 süstel (0,3 ml) ja 1 süstlanõel (27G1/2)
English: This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium- free'
Estonian: See ravimpreparaat sisaldab alla 1 mmol naatriumit (23 mg) annuse kohta, st on praktiliselt "naatriumivaba".
English: NeoRecormon 5000 IU solution for injection in pre-filled syringe One pre-filled syringe with 0.3 ml solution for injection contains 5000 international units (IU) corresponding to 41.5 micrograms epoetin beta* (recombinant human erythropoietin).
Estonian: Üks süstel 0,3 ml süstelahusega sisaldab 5000 RÜ (41,5 µg) epoetiin beetat* (rekombinantne inimese erütropoetiin).
English: - Subcutaneous administration:
Estonian: Korrektsioonifaas - Subkutaanne manustamine:
English: Additional side effects in adults receiving chemotherapy for cancer · Increase in blood pressure and headache may occasionally occur.
Estonian: • Mõnikord võib tekkida vererõhu tõus ja peavalu.
English: 4 pre-filled syringes (0.6 ml) and 4 needles (27G1/2)
Estonian: 4 süstlit (0,6 ml) ja 4 süstlanõela (27G1/2)
English: MINIMUM PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 500 IU pre-filled syringe
Estonian: VÄLISPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED VÄLISPAKEND 500 RÜ süstel
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 pre-filled syringe contains 500 IU epoetin beta.
Estonian: TOIMEAINE(TE) SISALDUS 1 süstel sisaldab 500 RÜ epoetiin beetat.
English: The initial dose for injections into veins is 40 IU per injection for every 1 kg of your body weight, given three times per week.
Estonian: Algannus veenisiseseks süstimiseks on 40 RÜ kehakaalu kg kohta kolm korda nädalas.
English: INFORMATION IN BRAILLE neorecormon 5000 IU
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) neorecormon 5000 RÜ
English: NeoRecormon 3000 IU solution for injection in pre-filled syringe One pre-filled syringe with 0.3 ml solution for injection contains 3000 international units (IU) corresponding to 24.9 micrograms epoetin beta* (recombinant human erythropoietin).
Estonian: Üks süstel 0,3 ml süstelahusega sisaldab 3000 RÜ (vastab 24,9 µg epoetiin beetale) epoetiin beetat* (rekombinantne inimese erütropoetiin).
English: STATEMENT OF ACTIVE SUBSTANCE(S) 1 pre-filled syringe contains 3000 IU epoetin beta.
Estonian: TOIMEAINE(TE) SISALDUS 1 süstel sisaldab 3000 RÜ epoetiin beetat.
English: EXP The reconstituted solution is stable for 1 month if stored at 2°C - 8°C (in a refrigerator)
Estonian: Temperatuuril 2 °C...8 °C (külmkapis) püsivad valmislahuse omadused stabiilsena 1 kuu
English: NeoRecormon 4000 IU solution for injection in pre-filled syringe One pre-filled syringe with 0.3 ml solution for injection contains 4000 international units (IU) corresponding to 33.2 micrograms epoetin beta* (recombinant human erythropoietin).
Estonian: Üks süstel 0,3 ml süstelahusega sisaldab 4000 RÜ (vastab 33,2 µg epoetiin beetale) epoetiin beetat* (rekombinantne inimese erütropoetiin).
English: NAME OF THE MEDICINAL PRODUCT NeoRecormon 500 IU solution for injection in pre-filled syringe Epoetin beta
Estonian: RAVIMPREPARAADI NIMETUS NeoRecormon 500 RÜ süstelahus süstlis Epoetiin beeta
English: NAME OF THE MEDICINAL PRODUCT NeoRecormon Multidose 50,000 IU lyophilisate and solvent for solution for injection
Estonian: RAVIMPREPARAADI NIMETUS NeoRecormon, Multidose 50 000 RÜ, süstelahuse lüofilisaat ja lahusti
English: INFORMATION IN BRAILLE neorecormon 10.000 IU
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) neorecormon 10 000 RÜ
English: The initial dose is 250 IU per injection for every 1 kg the infant weighs, three times a week.
Estonian: Lahust manustatakse naha alla 250 RÜ/kg 3 korda nädalas.